Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Accumulated Expenses (2022 - 2025)

Taysha Gene Therapies' Accumulated Expenses history spans 4 years, with the latest figure at $5.3 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses changed N/A year-over-year to $5.3 million; the TTM value through Sep 2025 reached $5.3 million, changed N/A, while the annual FY2024 figure was $5.2 million, 51.2% up from the prior year.
  • Accumulated Expenses for Q3 2025 was $5.3 million at Taysha Gene Therapies, down from $12.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $13.6 million in Q1 2024 and bottomed at $1.5 million in Q1 2025.
  • The 4-year median for Accumulated Expenses is $5.3 million (2024), against an average of $5.9 million.
  • The largest annual shift saw Accumulated Expenses soared 51.2% in 2024 before it plummeted 88.81% in 2025.
  • A 4-year view of Accumulated Expenses shows it stood at $2.5 million in 2022, then skyrocketed by 37.63% to $3.5 million in 2023, then skyrocketed by 51.2% to $5.2 million in 2024, then grew by 2.0% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Accumulated Expenses are $5.3 million (Q3 2025), $12.2 million (Q2 2025), and $1.5 million (Q1 2025).